Hematological Malignancies
135
23
32
54
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
22 trials with published results (16%)
Research Maturity
54 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
6.7%
9 terminated out of 135 trials
85.7%
-0.8% vs benchmark
8%
11 trials in Phase 3/4
41%
22 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (135)
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Durvalumab and Tremelimumab for Pediatric Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Study of AZD9829 in CD123+ Hematological Malignancies
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France